Latest Media Releases (Page 6) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Careteq 2022 Annual Report (ASX:CTQ)

CARETEQ is an ASX-listed, health-tech company delivering a portfolio of innovative solutions in the aged care and healthcare sectors. Founded in 2016 with the mission of improving wellbeing for all ...read more

Careteq - Appendix 4E (ASX:CTQ)

To view the appendix, download the attached PDF.

CARETEQ Q4-FY22 Activities Report and Appendix 4C (ASX:CTQ)

Highlights: -- Careteq’s pipeline expands five-fold in 4QFY22 vs. the previous quarter with over 60 active leads across the US and Australia -- The Group is generating interest from a wide...read more

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

MELBOURNE, AUSTRALIA 29 July 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform for cancer treatment and it...read more

Arovella Therapeutics - Sumatriptan Update (ASX:ALA)

MELBOURNE, AUSTRALIA 28 June 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery...read more

Arovella Therapeutics - ZolpiMist Launch Australia (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and con...read more

CARETEQ - 3Q-FY22 Activities Report & Appendix 4C (ASX:CTQ)

Highlights: * Careteq achieves several milestones in the quarter and advances on significant opportunities in Australia and North America, as highlighted in Careteq’s prospectus * Further ...read more

CARETEQ - Clarification of Appendix 3X & Appendix 3Y - M Simari (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) advises the following in relation to the Appendix 3X as lodged for Mr Simari on 11 January 2022: * The Appendix 3X was...read more

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

MELBOURNE, AUSTRALIA 28 April 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray deliver...read more

Careteq & RMIT sign Research Collaboration Agreement (ASX:CTQ)

Highlights: * Leading Victorian university RMIT University will work with Careteq to develop new assistive living technology solutions to expand on Careteq’s proprietary Sofihub platform *...read more

Arovella Therapeutics - Services Agreement with Q-Gen for CAR19-iNKT manufacture (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers, is pleased to announce that it has agr...read more

Arovella Therapeutics - Anagrelide patent for the United States (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers and a leader in oro-mucosal drug delive...read more

CARETEQ - Executive Leadership Team Restructured For Growth (ASX:CTQ)

Careteq Limited (ASX:CTQ, "Careteq" or the "Group") is pleased to announce the restructuring of the executive leadership team to better take advantage of the many growth opportun...read more

CARETEQ - Half Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

CARETEQ - Appendix 4D & Half Year Results (ASX:CTQ)

Highlights: -- Interim revenue jumps >6 times to $1.9m due to Ward MM acquisition and sharp increase in active SaaS platform users -- Number of users grows 579% pcp to >3k and Ward MM prof...read more

Viewing: 76 - 90 of 200 Previous | Next